CAR-T therapies can achieve remarkable efficacy in the treatment of haematological cancers, but the risk of side effects means that the cell infusions are almost always ad
While ASCO 2023 didn’t have too much focus on cell therapies, because of their lack of impact so far on the solid tumour space, Kite, a Gilead company, did share new data on Yescarta for la
A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro
Gilead Sciences and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel; axi-cel) for
Gilead Sciences' investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.<
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.